Desonide gel - Ortho Dermatologics/LEO Pharma

Drug Profile

Desonide gel - Ortho Dermatologics/LEO Pharma

Alternative Names: Desonate; Desonide hydrogel

Latest Information Update: 07 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dow Pharmaceutical Sciences; SkinMedica
  • Developer LEO Pharma; Ortho Dermatologics
  • Class Anti-inflammatories; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis

Most Recent Events

  • 04 Sep 2018 Bayer transferred prescription dermatology business to LEO Pharma in the United States
  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 19 Dec 2012 SkinMedica has been acquired by Allergan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top